Last reviewed 2026-04-22 · How we verify

Cohort HIVOL, patients infected by HIV

Centre Hospitalier Universitaire de Saint Etienne · FDA-approved active Biologic

Cohort HIVOL, patients infected by HIV is a Biologic drug developed by Centre Hospitalier Universitaire de Saint Etienne. It is currently FDA-approved for HIV infection (observational cohort study). Also known as: Blood and urinary samples.

Cohort HIVOL is a clinical cohort study monitoring HIV-infected patients, not a drug with a specific mechanism of action.

Cohort HIVOL is a clinical cohort study monitoring HIV-infected patients, not a drug with a specific mechanism of action. Used for HIV infection (observational cohort study).

At a glance

Generic name	Cohort HIVOL, patients infected by HIV
Also known as	Blood and urinary samples
Sponsor	Centre Hospitalier Universitaire de Saint Etienne
Modality	Biologic
Therapeutic area	Infectious Disease
Phase	FDA-approved

Mechanism of action

Cohort HIVOL appears to be an observational research cohort established by Centre Hospitalier Universitaire de Saint Etienne to study HIV-infected populations. It is a patient registry or longitudinal study rather than a pharmaceutical intervention with a defined molecular mechanism.

Approved indications

HIV infection (observational cohort study)

Common side effects

No common side effects on file.

Key clinical trials

5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cohort HIVOL, patients infected by HIV CI brief — competitive landscape report
Cohort HIVOL, patients infected by HIV updates RSS · CI watch RSS
Centre Hospitalier Universitaire de Saint Etienne portfolio CI

Frequently asked questions about Cohort HIVOL, patients infected by HIV

What is Cohort HIVOL, patients infected by HIV?

Cohort HIVOL, patients infected by HIV is a Biologic drug developed by Centre Hospitalier Universitaire de Saint Etienne, indicated for HIV infection (observational cohort study).

How does Cohort HIVOL, patients infected by HIV work?

Cohort HIVOL is a clinical cohort study monitoring HIV-infected patients, not a drug with a specific mechanism of action.

What is Cohort HIVOL, patients infected by HIV used for?

Cohort HIVOL, patients infected by HIV is indicated for HIV infection (observational cohort study).

Who makes Cohort HIVOL, patients infected by HIV?

Cohort HIVOL, patients infected by HIV is developed and marketed by Centre Hospitalier Universitaire de Saint Etienne (see full Centre Hospitalier Universitaire de Saint Etienne pipeline at /company/centre-hospitalier-universitaire-de-saint-etienne).

Is Cohort HIVOL, patients infected by HIV also known as anything else?

Cohort HIVOL, patients infected by HIV is also known as Blood and urinary samples.

What development phase is Cohort HIVOL, patients infected by HIV in?

Cohort HIVOL, patients infected by HIV is FDA-approved (marketed).

Manufacturer: Centre Hospitalier Universitaire de Saint Etienne — full pipeline
Therapeutic area: All drugs in Infectious Disease
Indication: Drugs for HIV infection (observational cohort study)
Also known as: Blood and urinary samples
Compare: Cohort HIVOL, patients infected by HIV vs similar drugs
Pricing: Cohort HIVOL, patients infected by HIV cost, discount & access